Search Results - "Palluzzi, E."

Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance: Still getting any benefit? A case-control study by Marchetti, C., Rosati, A., Scaletta, G., Pietragalla, A., Arcieri, M., Ergasti, R., Palluzzi, E., Scambia, G., Fagotti, A.

“…The role of secondary cytoreductive surgery (SCS) in platinum-sensitive recurrent ovarian cancer (PSROC) is still controversial. We investigated the role of…”
Get full text

Optimizing the number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma: A propensity-score matching analysis by Marchetti, C., Rosati, A., De Felice, F., Boccia, S.M., Vertechy, L., Pavone, M., Palluzzi, E., Scambia, G., Fagotti, A.

“…Neoadjuvant chemotherapy and interval debulking surgery are now widely offered in ovarian cancer patients unsuitable for surgery; the number of preoperative…”
Get full text

First-line carboplatin/nab-paclitaxel in advanced ovarian cancer patients, after hypersensitivity reaction to solvent-based taxanes: a single-institution experience by Parisi, A., Palluzzi, E., Cortellini, A., Sidoni, T., Cocciolone, V., Lanfiuti Baldi, P., Porzio, G., Ficorella, C., Cannita, K.

“…One of the major challenges related to solvent-based taxanes administration in clinical practice is the high rate of hypersensitivity reactions (HSRs)…”
Get full text

Bioclinical Parameters Driving Decision-Making of Subsequent Lines of Treatment in Metastatic Castration-Resistant Prostate Cancer by Irelli, A., Bruera, Gemma, Cannita, Katia, Palluzzi, E., Gravina, Giovanni Luca, Festuccia, Claudio, Ficorella, Corrado, Ricevuto, Enrico

“…Different options are available as second-line treatment of metastatic castrate-resistant prostate cancer: cabazitaxel, abiraterone, and enzalutamide. Phase…”
Get full text

752P PARP-inhibitors beyond progression: A new way to manage oligometastatic ovarian cancer recurrence by Palluzzi, E., Marchetti, C., Cappuccio, S., Avesani, G., Nardangeli, A., Scambia, G., Fagotti, A.

Get full text

Focus on Trabectedin in Ovarian Cancer: What Do We Still Need to Know? by Boccia, Serena Maria, Sassu, Carolina Maria, Ergasti, Raffaella, Vertechy, Laura, Apostol, Adriana Ionelia, Palluzzi, Eleonora, Fagotti, Anna, Scambia, Giovanni, Marchetti, Claudia

“…In the era of single and combination maintenance therapies as well as platinum and Poly (ADP-ribose) polymerase inhibitors (PARPi) resistance, the choice of…”
Get full text

52P Real-world data of niraparib in platinum sensitive relapsed ovarian cancer: A multicenter experience of the MITO group by Musacchio, L., Palluzzi, E., Lauria, R., Di Napoli, M., Corrado, G., Bergamini, A., Salutari, V., Marchetti, C., Angioli, R., Cassani, C., Gori, S., Palaia, I., Savarese, A., Raspagliesi, F., Mosconi, A.M., Zafarana, E., De Angelis, C., Ferrandina, G., Scambia, G., Lorusso, D.

Get full text

1633 - Bisphosphonates in Bone Metastatic Patients: Experience of Medical Oncology, University of L'Aquila Over 17 Years by Ricevuto, E., Irelli, A., Cannita, K., Bruera, G., Baldi, P. Lanfiuti, Cocciolone, V., Palluzzi, E., Rinaldi, L., Teti, A., Ficorella, C.

“…Three hundred and twenty-nine bone metastatic patients (BMP) followed at Medical Oncology Division, San Salvatore Hospital L'Aquila from 1995 were evaluated…”
Get full text

Bisphosphonates in Bone Metastatic Patients: Experience of Medical Oncology, University of L'Aquila Over 17 Years by Ricevuto, E., Irelli, A., Cannita, K., Bruera, G., Baldi, P. Lanfiuti, Cocciolone, V., Palluzzi, E., Rinaldi, L., Teti, A., Ficorella, C.

Get full text